Drug intelligence / Profile preview

TC-071

Development stage: Preclinical
Lead developer: TiCARos Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous (inferred From Standard Practice For Car-t Therapies)

Overview

TC-071 is a chimeric antigen receptor T-cell (CAR-T) therapy under preclinical development, originally developed by Ticaros. It is being investigated primarily for the treatment of multiple myeloma and other neoplasms, as well as immune system and cardiovascular diseases. The specific target or mechanism of action has not been disclosed in public sources, but it is classified as a CAR-T cell therapy[1][2]. There are no clinical trials or regulatory approvals reported for this drug to date[2].

Beyond the preview

Go deeper on TC-071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC-071.

Explore the full profile